DISCLAIMER
The information and materials accessed through or made available for use on any of our Sites, including, any information about diseases, conditions, treatments, or medicines, are for informational purposes only. The Content is not intended to be and is not a substitute for professional medical advice, diagnosis, or treatment, and your participation on our Sites does not create a healthcare professional-patient relationship. You should consult a doctor or other qualified health care professional regarding any questions you have about your health or before making any decisions related to your health or wellness. Call your doctor or 911 immediately if you think you may have a medical emergency.message sent
email sent successfully
| You are receiving this because you have an account on www.oneGRAVESvoice.com | ||
| To unsubscribe from these emails, click here |
Trusted Resources: News & Meetings
Latest announcements and gatherings
Teprotumumab for Treatment of Thyroid Eye Disease Meets Endpoints in Phase 3 Study
Results from the phase 3 OPTIC study showed more patients treated with teprotumumab had a meaningful improvement in proptosis compared with those who received placebo.
The confirmatory trial evaluated teprotumumab for the treatment of active thyroid eye disease.
The primary endpoint of the study was met, with 82.9% of 41 teprotumumab-treated patients achieving a 2 mm or more reduction of proptosis compared with 9.5% of 42 placebo patients, a statically significant difference (P < .001), according to a press release from Horizon Pharma.
All secondary endpoints were met in the study. A greater percentage of teprotumumab-treated patients experienced a 2 point or greater reduction in clinical activity score and a 2 mm or greater reduction in proptosis from baseline, with no deterioration in clinical activity score or proptosis in the fellow eye, compared with the placebo group.
myBinderRelated Content
-
People & PlacesLaura Periman, MDLaura Periman, MD is a board-certified o...
-
Videos & VisualsNo Need to Suffer From Double Vision With Graves’ Diseasehttps://www.youtube.com/watch?v=cQ7-Yi5t...
-
Evidence & EducationPatients’ Expectations for the Functional and Psychosocial Outcomes of Orbital Decompression Surgery for Thyro...Patients with appearance-altering condit...
-
Videos & VisualsTreatment Options for Thyroid Eye or Graves’ Disease at Ohio Statehttps://www.youtube.com/watch?v=2vcbs9hu...
-
People & PlacesSandy Zhang-Nunes, MDSandy Zhang-Nunes, MD, earned her underg...
-
Evidence & EducationHyperthyroidism: Graves’ OphthalmopathyGraves' ophthalmopathy, also called thyr...
-
Videos & VisualsBritish Thyroid Foundation Meet the Experts webinar — TED: What you need to knowhttps://www.youtube.com/watch?v=iFe1Fx5F...
send a message
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.